SB 204144 is an HIV protease inhibitor. SB 204144 can be used in research on immune system diseases.

E3709 is an antibacterial agent. E3709 exhibits significant inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA), Enterococcus faecalis, streptococci, Clostridia, and diphtheroids. E3709 can be used for research related to Gram-positive bacterial infections.

DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics.

ABT-255 hydrochloride is an orally active anti-bacterial agent. ABT-255 hydrochloride exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin- or Ethambutol-resistant Mycobacterium tuberculosis. ABT-255 hydrochloride shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 hydrochloride can be used for the study of pulmonary tuberculosis.

AJI-9561 is a benzoxazole derivative produced by Streptomyces sp. AJI-9561 exhibits cytotoxicity and antibacterial activity. AJI-9561 inhibits the proliferation of Jurkat T cells and mouse P388 leukemia cells, with its IC50 being 0.88 and 1.63 μM respectively. AJI-9561 can be used for research on anti-cancer and antibacterial properties.

HCV-371 is a highly selective, potent, and low cytotoxicity HCV NSSB (EC50 = 4.8-6.1 μM) polymerase allosteric inhibitor. HCV-371 can be used for research on hepatitis C virus infection.

Jun6504 is an enterovirus 2C inhibitor. Jun6504 shows potent and broad-spectrum antiviral activity against multiple strains of EV-D68 (EC50 = 250 nM), EV-A71 (EC50 = 502.4 nM), and CVB3 (EC50 = 1049 nM). Jun6504 improves paralysis score and weight gain in a neonatal mouse model of EV-D68 infection. Jun6504 reduces viral titers in the spinal cord and the infected quadriceps muscle. Jun6504 can be used for EV-D68 antiviral research.

AVI-4206 is a selective Mac1 inhibitor with an lC50 of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of SARS-CoV-2 infection. AVI-4206 can be used the study of SARS-CoV-2 infection.

MMV665917 is an orally active piperazine derivative with anti-Cryptosporidium parvum activity with an EC90 of 15 μM. MMV665917 significantly reduces the parasite load in a porcine model infected with C. hominis, decreases ovarian excretion, alleviates diarrhea symptoms and reduces intestinal mucosal damage. MMV665917 can be used for research on Cryptosporidium parvum disease.

WJM664 is a potent Plasmodium falciparum PfATP4 inhibitor. WJM664 shows strong activity against malaria parasites. WJM664 blocks gamete development and transmission to mosquitoes by inhibiting PfATP4-mediated Na+-dependent ATPase activity, and acts on multiple stages of the malaria parasite life cycle.

KR-26556 is a sulfonamide type hepatitis B virus (HBV) capsid assembly regulator. KR-26556 exhibits anti-HBV activity with an EC50 of 0.04 μM. KR-26556 has favorable safety characteristics. KR-26556 can be used for research on chronic hepatitis B.

KY-9 is an antibacterial active compound.

JSZ16 is a Succinate dehydrogenase (SDH) inhibitor with an IC50 of 30.3  μM. JSZ16 has potent broad-spectrum fungicidal activity, such as Sclerotinia sclerotiorum, Botrytis cinerea and Colletotrichum fragariae, with an EC50 of 4.4 mg/L for Sclerotinia sclerotiorum. JSZ16 influences the cell membrane permeability of pathogenic fungi. JSZ16 can be used for the development of fungicide.

CGR-50 is a potent RSV fusion glycoprotein (F protein) inhibitor (EC50 = 32.6 nM against RSV A2 in HEp-2 cells). CGR-50 blocks RSV entry by binding to the F protein and inhibiting membrane fusion. CGR-50 can be used for RSV infection research.

QPyN16Th is an N-palmitoylated cationic thiazolidine antibiotic. QPyN16Th is selectively active against the Gram-positive bavteria E. faecalis, S. aureus and MRSA with an MIC of 1.95 μM over gram-negative bacteria. QPyN16Th can induce membrane permeabilization and depolarization and ROS production in MRSA. QPyN16Th increases the survival of zebrafish model of intramuscular MRSA infection.

Acetoxycycloheximide is an antibiotic with antitumor activity. Acetoxycycloheximide a protein synthesis inhibitor. Acetoxycycloheximide significantly induces activation of procaspase-3 and subsequent apoptosis mediated by the Cytochrome c from mitochondria via activation of JNK pathway. Acetoxycycloheximide triggers the downregulation of cell surface TNF-R1 via the activation of ERK and p38 MAPK, thereby preventing activation of the NF-κB signaling pathway by TNF-α. Acetoxycycloheximide is much more toxic to female rats than to males. Acetoxycycloheximide can be used for inflammatory and immune diseases and cancers research.

CCC-0975 is a hepatitis B virus (HBV) inhibitor (EC50=10 μM). CCC-0975 interferes with the conversion of relaxed circular DNA (rcDNA) to cccDNA, synchronously reducing cccDNA and its precursor deproteinized rcDNA (DP-rcDNA) without promoting their intracellular degradation. CCC-0975 is promising for research of chronic hepatitis B.

GLK7-001 is a Trypanosoma cruzi glucokinase (TcGlcK) inhibitor. GLK7-001 has in vitro trypanocidal activity.

FCE-20696 (hydrochloride) is an orally active immunomodulator. FCE-20696 (hydrochloride) also shows anti-inflammation and anti-infection effects. FCE-20696 (hydrochloride) can be used for the researches of infection, inflammation and immunology, such as adjuvant arthritis.

CP-74667 is a quinolone antibacterial agent. CP-74667 shows high activity against Xanthomonas maltophilia (MIC50 = 1 μg/mL), Staphylococcus spp. (MIC50 = 0.06-0.12 μg/mL) and enterococci (MIC50 = 0.5-4 μg/mL).

E 5065 is an orally active antibacterial agent. E 5065 exhibits potent in vitro activity against Gram-negative microorganisms, Gram-positive cocci, and anaerobes. E 5065 exhibits an MIC90 of 0.5 μg/mL against Clostridium spp. E 5065 provides protection against experimental infections caused by P. aeruginosa.

PNU-183792, a 4-oxo-dihydroquinoline, is an orally active HSV polymerases inhibitor. PNU-183792 shows a broad-spectrum antiviral activity, with IC50 values of 0.69 μM, 0.37 μM and 0.58 μM for human cytomegalovirus (HCM), varicella zoster virus and HSV polymerases, respectively. PNU-183792 is inactive against human α, γ and δ polymerases. PNU-183792 also inhibits simian varicella virus (SVV), murine cytomegalovirus (MCMV) and rat cytomegalovirus (RCMV).

ML370 is an antibacterial agent. ML370 exerts antibacterial activity by inhibiting the activity of Vibrio cholerae LuxO kinase. ML370 can be used in the research of infectious diseases such as cholera.

AT-61 is a non nucleoside HBV replication inhibitor. AT-61 prevents the capsid formation of pre genomic RNA, resulting in the production of empty capsids. AT-61 has the activity of drug-resistant mutant strains. AT-61 can be used for research on hepatitis B virus infection.

ABT-255 free base is an orally active anti-bacterial agent. ABT-255 free base exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin- or Ethambutol-resistant Mycobacterium tuberculosis. ABT-255 free base shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 free base can be used for the study of pulmonary tuberculosis.

Jun15799 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 0.8, 21.1 and 3.0 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15799 has a significant antiviral activity against EV-D68 US/MO/14-18947, EV-A71 Tainan/4643/1998 and CVB3 Nancy cells (EC50s of 0.3, 11.4 and 0.3 μM, respectively). Jun15799 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis.

Jun15716 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 15.9, 44.2 and 17.8 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15716 has a potent antiviral activity against EV-D68 US/MO/14-18947 and CVB3 Nancy cells (EC50s of 1.0 and 0.7 μM, respectively). Jun15716 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis.

FL-166 is a SARS coronavirus main protease (Mpro) inhibitor (Ki: 40 nM). FL-166 exerts its inhibitory effect by targeting a cluster of serine residues near the active site of the protease. FL-166 can be used in the study of SARS-CoV.

KP 736 (sodium) is a broad-spectrum antibacterial agent. KP 736 (sodium) exhibits excellent broad-spectrum anti Gram negative bacterial activity in vitro, especially effective against Pseudomonas aeruginosa and multiple drug-resistant bacteria. KP 736 (sodium) can be used for research on bacterial infections.

VNRX-9945 is a potent, broadly and orally active HBV CAM (capsid assembly modulator) with an EC50 of 2.6 nM. VNRX-9945 exhibits excellent and broad antiviral activity against multiple HBV genotypes in vitro, along with favorable pharmacokinetic profiles across multiple species. VNRX-9945 demonstrates robust antiviral efficacy in the adeno-associated virus mice models of HBV (AAV-HBV) infection.